Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: Correlation with Sokal prognostic index and haematological control

T. P. Hughes, A. Grigg, J. Szer, J. Ho, D. Ma, B. M. Dale, R. M. Green, J. E. Norman, R. E. Sage, R. Herrmann, P. Cannell, A. P. Schwarer, K. Taylor, K. Atkinson, C. Arthur

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Mobilization of Philadelphia chromosome (Ph) negative blood progenitors was attempted in 23 newly diagnosed chronic myeloid leukaemia (CML) patients using a regimen of cyclophosphamide (CY) 5 g/m 2 and rHUG-CSF 150 μg/m 2 daily. This regimen was well tolerated with no major adverse events reported. More than 2x 10 6 /kg CD34 + cells were collected in 21 patients (91%). Predominantly Ph-negative mobilization (0-25% Ph-positive) was seen in 30% of cases overall and was confined to patients with a Sokal prognostic score < 1 (7/11 with Sokal score <1; 0/12 with Sokal score ≤1). Within the low Sokal index group, a low WBC count pre-mobilization and a low WBC nadir both correlated strongly with Ph-negative mobilization (P = 0.006 and 0.02 respectively). Five of 19 patients receiving at least 6 months of Roferon A therapy post mobilization achieved a major cytogenetic response: all five patients were Ph-negative mobilizers. Therefore CML patients can be divided into a good-prognosis group in whom predominantly Ph-negative progenitors can be mobilized using a regimen of moderate intensity if haematological control is achieved premobilization, and a poor-prognosis group for whom predominantly Ph-positive cells are mobilized with this regimen regardless of haematological control.

Original languageEnglish
Pages (from-to)635-640
Number of pages6
JournalBritish Journal of Haematology
Volume96
Issue number3
DOIs
Publication statusPublished - 4 Mar 1997

Keywords

  • Autograft
  • CML
  • Cyclophosphamide
  • G-CSF
  • Mobilization
  • Sokal

ASJC Scopus subject areas

  • Hematology

Cite this